Outcomes of dilation and evacuation with and without feticide by intra-cardiac potassium chloride injection: a service evaluation. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Con(2018Con( ), doi:10.1016Con( /j.contraception.2018 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Study design: We evaluated outcomes with D&E at 18-24 weeks' gestation in the 6 months before and 6 months after removing feticide with KCL from the guidelines of a national British abortion provider. We extracted demographic and procedure-related data from medical records and electronic databases. We surveyed women undergoing D&E in both time periods about acceptability and side effects.
Introduction
Fetal demise is induced before dilation and evacuation (D&E) by some abortion providers in the belief that it facilitates an easier, faster and safer evacuation [1] . Other frequently cited reasons for this practice are patient preference [2, 3] , avoiding prosecution [4] , and avoiding extramural delivery with signs of life [1, 5] .
The most commonly used methods of inducing fetal demise before a D&E are intra-amniotic or intra-fetal injection of digoxin, and fetal intra-cardiac potassium chloride (KCL) injection [1] . Research is limited, but the few existing comparative studies suggest that these methods do not confer a clinical benefit and may increase risks. A randomized controlled trial of intraamniotic digoxin injection found no reduction in D&E procedure duration, difficulty, or blood loss compared to placebo, but an increased risk of vomiting [2] . Extramural delivery, hospitalization, and signs of infection have also been reported as more frequent with digoxin use before D&E than with non-use [6] . The only comparative study of feticide with intracardiac KCL is a retrospective review of D&Es performed after KCL (n=23), without feticide (n=53), and for spontaneous fetal demise (n=52) [7] . Feticide with intra-cardiac KCL did not reduce anesthesia (operative) time or blood loss but was associated with a higher risk of cervical laceration. Although complications with the administration of fetal intra-cardiac KCL are rare [8, 9] chorioamnionitis has been reported with its use in the setting of selective fetal reduction [10] and one case report of maternal cardiac arrest due to inadvertent intravascular injection has been published [11] .
British Pregnancy Advisory Service (BPAS) is a non-profit abortion provider with clinics in
England, Scotland and Wales. The organization performs approximately 60,000 abortions annually of which over 1,800 are D&Es between 18 and 24 weeks' gestation. Since 2004, the BPAS guidelines have stipulated feticide with KCL as standard practice before surgical abortions performed at 22-23+6 weeks' gestation. In 2008, the criteria for feticide were expanded to also include pregnancies at 18-21+6 weeks' gestation when coupled with one
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D&E with and without feticide 4 or more of the following characteristics: age ≤18 years, or body mass index (BMI) ≥33, or ≥2
Cesarean deliveries.
The BPAS Clinical Governance Committee reconsidered the inclusion of feticide in the organization's D&E guidance following the publication of research suggesting that the risks with feticide outweigh the benefits, and the conclusion in US guidelines [1, 12] that there is insufficient evidence to recommend feticide to increase the safety of D&E. The committee decided to remove feticide from the BPAS guidelines on D&E but wished to actively monitor the impact of this change in longstanding practice. This paper reports on the findings of that evaluation which spanned the 6 months prior to and the 6 months after the guideline changed.
Materials and methods
We conducted an evaluation at the three BPAS clinics in England where D&E with KCL was performed. To allow an even number of months for each cohort, we reviewed routinely collected data from all D&Es with KCL in the 6 months before its removal from organizational guidance and for all D&Es that would have met criteria for KCL in the 6 months after its removal. The criteria for feticide were 1) gestational age of 22-23+6 weeks, or 2) gestational age of 18-21+6 weeks combined with one or more of the following characteristics: age ≤18 years, or body mass index (BMI) ≥33, or ≥2 Cesarean deliveries. The nurse undertaking the abortion consultation provided women with written and verbal information about the evaluation and obtained consent for the treatment to be provided. All BPAS clients receive written information about how their anonymized data may be accessed for use, including service evaluations and research.
A C C E P T E D M A N U S C R I P T
From February-July 2014, a fetal intra-cardiac KCL injection followed by insertion of osmotic cervical dilators was performed the day prior to evacuation (Day 1). Using ultrasound, the surgeon confirmed correct placement of a 16-cm 17-gauge Chiba needle (Cook Ob/Gyn, IN, USA) in the fetal ventricle and injected 1-3 ml of a 15% KCL solution. If asystole was not observed, the surgeon gave further doses of KCL. Immediately after the injection, the surgeon inserted Dilapan osmotic cervical dilators (4mm x 65mm). The number of dilators to be inserted was not stipulated in BPAS' guidance. Antibiotic prophylaxis with azithromycin one gram orally once or doxycycline 100 mg orally twice per day for seven days was administered following feticide and dilator insertion [5] .
Women were discharged and returned the next day for evacuation (Day 2). Adjunctive misoprostol was administered after admission to the clinic. The recommended regime for adjunctive misoprostol was misoprostol 400 mcg vaginally for 3 hours or sublingually for 2
hours. In cases of inadequate dilation, women received additional doses of misoprostol and/or osmotic dilators for 3 more hours. If the surgeon determined the dilation was insufficient to safely complete the procedure, additional dilators were placed for another 24 hours and the evacuation performed on Day 3.
Evacuations were undertaken under general anesthesia with propofol and fentanyl, without intubation. Additional antibiotic prophylaxis with metronidazole one gram per rectum was administered immediately post-operatively [5] . The use of prophylactic or indicated uterotonics was left to the discretion of the surgeon. Eight experienced providers performed all procedures, of which six performed most of the evacuations across both time periods; one provider performed 3 procedures with KCL and none without KCL and one performed 3
procedures without KCL and none with KCL.
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From August 2014-January 2015, the use of feticide was removed from organizational D&E guidelines. Those women who would have previously met criteria for feticide had Dilapan placed on Day 1 while awake. Cervical anesthesia was not used for insertion. All other procedures were performed as described.
We extracted demographic data and data on procedures and complications from the case note onto a data collection form. Procedure start and end times were recorded by a health care assistant from a clock in the theater and reflect the time from the first instrument inserted into the vagina to the last instrument removed from the vagina. The times were recorded in hours and minutes. A nurse administered surveys about nausea, vomiting, pain, and cramping between feticide and/or dilator placement and the evacuation, and asked women to rank the severity and/or frequency of their symptoms. Women were also asked to rank the acceptability of the procedure they underwent (feticide and Dilapan insertion or Dilapan insertion alone) using a 5-point Likert scale. The nurse aimed to survey clients prior to the evacuation but in some cases the surveys were performed after the evacuation.
The primary outcomes were the duration of the D&E and 'any complication'. Complications were limited to those occurring at the time of the procedure. Complications were reported by the surgeon or a member of the theater team on incident reporting forms and coded using the organization's existing codes for incidents. The codes also indicated if the complication was major or minor. Major complications were: uterine perforation, hemorrhage (estimated blood loss ≥ 500 ml) requiring transfusion, uterine atony requiring more than one dose of utero-tonic medication or an additional intervention (e.g., uterine massage) or both, infection requiring hospitalization, exploratory laparoscopy or laparotomy, hysterectomy, pulmonary aspiration, adverse drug reaction requiring hospitalization, extramural delivery, and failed procedure. Minor complications were: cervical false passage, cervical laceration requiring
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repair, hemorrhage not requiring transfusion, uterine atony not requiring more than one dose of uterotonic medication or additional intervention, incomplete abortion, hematometra, infection not requiring hospitalization, vasovagal reaction, and adverse drug reaction not requiring hospitalization.
We generated descriptive statistics overall and by group (KCL and no-KCL). We used Chisquare, Fisher's Exact, Student's t, Wilcoxon rank sum, and Anova tests to assess differences by group in bivariate analyses. We used multivariable linear regression to assess the relationship between procedure duration and KCL, adjusted for other variables. We defined statistical significance as a two-tailed p-value of ≤0.05. Data were analyzed using STATA Statistical Software, release 13.0 (Stata-Corp., College Station, TX).
This project was approved by BPAS' Research and Ethics Committee (Ref. 2014/01/PL).

Results
Five-hundred forty-eight women were involved in the evaluation: 291 (53.1%) received feticide with KCL before their D&E and 257 (46.9%) did not receive feticide. Demographic characteristics, obstetrical history, body mass index (BMI), and gestational age were not different between groups (Table 1) . Most women were nulliparous (66.6%). Of those who were parous, 19.1% (n=36) had one or more prior Cesarean deliveries (18 per group). The mean gestational age in both groups was 22 weeks and 2 days. All but two of the pregnancies were singleton gestations.
We excluded five women from the analysis of outcomes. Three women in the KCL group did not return to the clinic for evacuation. In two cases, the women informed the clinic staff that
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D&E with and without feticide 8 they were unable to arrange or afford transportation. One of them presented to a local hospital two days later and delivered spontaneously. An induction of labor in a local hospital was organized for the second woman. In the third case, clinic staff members were unable to contact the woman to ascertain her reasons for not returning. The clinic was then contacted by a hospital consultant several weeks later when she presented in labor and delivered the demised fetus. Two women in the no-KCL group did not progress to a surgical evacuation.
One chose to continue the pregnancy and had the Dilapan removed. The other was deemed unsuitable for general anesthesia on Day 2 because of a chest infection. She had a medical induction in hospital.
Procedure details are summarized in Table 2 . Feticide with intra-cardiac KCL was administered under general anesthesia with propofol and fentanyl without intubation in 98% of cases. Local anesthesia was used in the remaining 2%. The mean volume of KCL administered was 6.2 ml (range 1.5-10 ml) and median length of time to complete the feticidal procedure and insert Dilapan was 8 minutes (range 5-28 minutes). Cervical preparation was undertaken with Dilapan in all cases, but fewer were placed when KCL was used. When KCL was administered, 0.3% (n=1) of women had 2 Dilapan inserted, 93.8% (n=273) received 3 Dilapan, and 5.8% (n=17) had 4 or more placed. In the period when KCL was omitted, 1.6% (n=4) had 2 Dilapan, 57.2% (n=147) had 3, and 41.2% (n=106) had 4 or more inserted. Age, parity, BMI, and number of Dilapan were not associated with procedure duration.
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There was no significant difference in overall complications between groups (7.3% KCL vs.
4.3% no-KCL, p=0.1) ( Table 4 ). Five women had major complications in the KCL group compared to 4 in the no-KCL group (1.7% vs. 1.6%, respectively, p=0.9). In the KCL group, these were 3 extramural deliveries following administration of adjunctive misoprostol, one case of major atony, and one hemorrhage resulting in disseminated intravascular coagulopathy, hysterectomy and uterine artery embolization in a woman with abnormal placentation. In the no-KCL group, major complications were two extramural deliveries, one case of major atony, and two failed procedures. In one of the procedure failures, the cervix
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A C C E P T E D M A N U S C R I P T was displaced due to fecal impaction and could not be reached by the surgeon. The client had a medical induction. In the other failed procedure, the surgeon was only able to partially complete the evacuation due to high and transverse fetal lie. Misoprostol and oxytocin were administered to bring the fetal parts into the lower part of uterus to facilitate extraction. An extramural delivery followed shortly after their initiation. The other extramural delivery occurred in the clinic after placement of a second set of Dilapan.
Total minor complications were not significantly different between groups (5.6% KCL vs.
3.1% no-KCL, p=0.2). However, there were significantly more cases of minor atony with KCL than without KCL (3.1% vs. 0%, respectively, p=0.004). This was despite appreciably more women in the KCL group receiving prophylactic utero-tonics (81.6% KCL vs. 72.6% no-KCL, p=0.01). There was no difference in hemorrhage or need for transfusion between groups.
More women in the no-KCL group had cervical lacerations requiring repair, but this was not 
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KCL, p=0.4). The proportion of women who rated their procedure as acceptable or very acceptable did not differ between groups (79.4% KCL vs. 87.0% no-KCL, p=0.2). The overall pattern of responses for side effects remained the same overall and stratified by timing of survey. Reported levels of nausea, vomiting, and pain were higher in the KCL group when the surveys were performed post-procedure but these were not statistically significantly different due to the small numbers of surveys done at this time.
Discussion
In this comparative service evaluation, we found that injection of fetal intra-cardiac KCL prior to D&E at 18-24 weeks' gestation was associated with a reduction in procedure duration of 3.5 minutes (95% CI 2.4-4.6) after adjustment for age, parity, Cesarean deliveries, gestation, BMI, surgeon, and number and duration of Dilapan in situ. Feticide with KCL was also associated with more reported nausea, pain at the injection site, and uterine atony. The KCL-associated reduction in procedure duration we observed was independent of other factors that also led to modest duration reductions (i.e., longer duration of Dilapan in situ) or of those that increased procedure duration (i.e., more Cesareans, greater gestational age).
These findings contrast with those of Jackson et. al, [2] who found no difference in procedure duration between intra-amniotic digoxin and a placebo injection, even within subgroupings by gestation, surgeon and parity. One potential explanation for this difference in findings is that the duration of fetal demise, and opportunity for subsequent softening of the fetal tissues and cervical ripening, is longer with KCL than digoxin. Potassium chloride induces asystole immediately compared to intra-amniotic digoxin, which can take 4 hours or more to cause fetal demise [13] . Intra-amniotic digoxin may also fail to induce demise in up to 8% of cases [1] . This may not be comparable when digoxin is administered intra-fetally, including into the fetal heart, however, which may lead to faster and/or immediate induction of demise. Alternatively it may be that the intense vasoconstriction known to be induced by
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high concentrations of KCL directly damages fetal tissues accelerating autolysis which facilitates the evacuation.
Our findings also differ from those in the small retrospective analysis by Singh et. al, [7] who found no reduction in procedure times when comparing D&Es with and without KCL or spontaneous demise One possible explanation for the increased operative time without KCL that we observed is that the surgeons, who had been performing D&E with KCL for many years, were unaccustomed to the feel of fetal tissue at advanced gestations without KCL. It is possible that, with time, their operative times would have decreased as they became used to approaching the cases in a way suited to less fetal maceration.
Complications were infrequent, and we found no difference in the overall number of cases with any complication, or in major or minor subgroupings with and without KCL. Neither extramural deliveries nor infection were higher with KCL than without KCL. Uterine atony requiring massage or administration of a single utero-tonic agent was significantly more common with KCL, despite more women in this group receiving prophylactic utero-tonics.
We are uncertain as to the reason for this finding. Although atony can be a very serious complication, there was no difference between groups in atony needing multiple interventions, hemorrhage or blood transfusions, potentially due to prophylactic interventions.
We documented that women receiving KCL reported more nausea. This side effect was most likely due to the fentanyl administered as part of the general anesthesia regimen used for the feticidal injection. Feticide with intra-cardiac KCL can be administered with local anesthesia [8] , which may have reduced this side effect as well as the injection site pain that
women reported. It is also notable that in all cases, the duration of time necessary to perform the feticidal injection exceeded the observed reduction in D&E procedure duration in all cases. Despite differences in discomfort and substantial differences in process, overall acceptability of treatment was high in both, and not different between, groups.
The main limitation of this evaluation is that it was not a randomized trial. We are, therefore, unable to state conclusively that KCL would influence outcomes with D&E differently from not using KCL if women were allocated at random. Although not randomized, we benefitted from a large sample and the groups were very similar, and particularly with regard to characteristics such as gestational age, multiple prior Cesareans and higher BMI, which have been shown to affect procedure duration or complications in other studies of D&E [16, 17, 18] . In addition, procedural variations introduced by surgeons when KCL was removed from organizational guidelines, such as using more Dilapan and leaving them in place longer, did not reduce procedure duration to the same degree as KCL administration. This suggests that the observed effect of KCL might have been greater had those variations not been introduced.
In conclusion, we found that feticide with intra-cardiac KCL is associated with a reduction in D&E procedure duration but with more reported pain, mainly at the injection site, and an increased occurrence of uterine atony. A randomized trial is necessary to confirm these results. Even if a reduction in D&E duration is demonstrable in a trial, this additional efficiency at the time of evacuation needs to be weighed against the need to provide advanced training to clinicians in safe and effective ultra-sound guided intra-fetal intracardiac injections, risks associated with the injection including those of sedation or general anesthesia if needed for administration, and the time necessary to perform the feticide injection. A C C E P T E D M A N U S C R I P T Data presented as n (%) or mean ± standard deviation, unless otherwise noted * KCL = feticide with intra-cardiac potassium chloride ** No-KCL= no feticide § n=288 for KCL group as three women did not return to BPAS for the evacuation, n=255 for no-KCL group as two women did not progress to surgical evacuation * KCL = feticide with intra-cardiac potassium chloride ** No-KCL= no feticide *** Requiring more than one dose of utero-tonic medication or an additional intervention or both ¥ Hemorrhage defined as estimated blood loss ≥ 500 ml § Not requiring more than one dose of uterotonic medication or additional intervention A C C E P T E D M A N U S C R I P T 
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